About The Study: In people with type 2 diabetes, both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) were statistically significantly associated with decreased risk of Alzheimer disease and related dementias compared with other glucose-lowering drugs, and no difference was observed between both drugs.
Corresponding Author: To contact the corresponding author, Jingchuan Guo, MD, PhD, email guoj1@ufl.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaneurol.2025.0353)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2025.0353?guestAccessKey=903463ed-188b-43f3-a655-a69f968d4580&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=040725
JAMA Neurology